Press Releases

Date	Title and Summary	Additional Formats
Toggle SummaryAug162017	Fate Therapeutics Announces Issuance of U.S. Patent Covering Use of Viral Transduction Enhancers in Gene Therapy Patent Broadly Protects the Use of Prostaglandins for Enhancing Gene Transfer in Blood Stem Cells Read All »	View HTML Fate Therapeutics Announces Issuance of U.S. Patent Covering Use of Viral Transduction Enhancers in Gene Therapy 15 KB
Toggle SummaryDec132017	Fate Therapeutics Announces Pricing of Public Offering of Common Stock SAN DIEGO, Dec. 13, 2017 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, today announced the pricing of an underwritten public offering of Read All »	View HTML Fate Therapeutics Announces Pricing of Public Offering of Common Stock 379.7 KB
Toggle SummaryDec122017	Fate Therapeutics Announces Proposed Public Offering of Common Stock SAN DIEGO, Dec. 12, 2017 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, today announced that it has commenced an underwritten public offering Read All »	View HTML Fate Therapeutics Announces Proposed Public Offering of Common Stock 379.4 KB
Toggle SummaryAug082017	Fate Therapeutics Announces Publication of Preclinical Data in Cancer Research and FDA Clearance of Third IND for FATE-NK100 Non-Clinical Studies Demonstrate Unique Anti-tumor Activity of Natural Killer Cell Product Candidate FDA Clears IND for FATE-NK100 in Ovarian Cancer SAN DIEGO, Aug. 08, 2017 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to the Read All »	View HTML Fate Therapeutics Announces Publication of Preclinical Data in Cancer Research and FDA Clearance of Third IND for FATE-NK100 18.4 KB
Toggle SummaryNov012017	Fate Therapeutics Announces Six Presentations at the 2017 ASH Annual Meeting Oral Presentation Unveiling Generation of CD8αβ + T Cells from Engineered Pluripotent Cell Line for Off-the-Shelf CAR T-Cell Cancer Immunotherapy Oral Presentation Highlighting GMP Production of iPSC-derived NK Cell Product Candidate FT500 to Support 1Q18 IND Filing Poster Presentation Releasing Read All »	View HTML Fate Therapeutics Announces Six Presentations at the 2017 ASH Annual Meeting 97.7 KB
Toggle SummaryDec112017	Fate Therapeutics Announces Successful Completion of Technology Transfer and Initiation of IND-Enabling Manufacture of FT500 SAN DIEGO, Calif., Dec. 11, 2017 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced today that IND-enabling production of FT500 has Read All »	View HTML Fate Therapeutics Announces Successful Completion of Technology Transfer and Initiation of IND-Enabling Manufacture of FT500 25.6 KB
Toggle SummarySep142017	Fate Therapeutics Appoints Jim Beitel as Senior Vice President, Corporate Development SAN DIEGO, Sept. 14, 2017 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced today that the Company has appointed Jim Beitel, M.B.A. Read All »	View HTML Fate Therapeutics Appoints Jim Beitel as Senior Vice President, Corporate Development 17 KB
Toggle SummarySep182017	Fate Therapeutics Initiates Phase 2 PROTECT Study of ProTmune™ for Prevention of Acute Graft-versus-Host Disease Independent Data Monitoring Committee Conducts Phase 1 Safety Review and Unanimously Recommends Opening of Phase 2 Enrollment First Seven Subjects Receiving ProTmune Clear Phase 1 Safety Objectives of Engraftment and Survival at Day 28 Phase 1 Day 100 Acute GvHD Data Expected to be Presented at Read All »	View HTML Fate Therapeutics Initiates Phase 2 PROTECT Study of ProTmune™ for Prevention of Acute Graft-versus-Host Disease 19.4 KB
Toggle SummaryMay152017	Fate Therapeutics Reports First Quarter 2017 Financial Results ProTmune™ PROTECT Safety Data Expected in Mid-2017 Launched First-in-Human Clinical Trial of FATE-NK100 for Acute Myelogenous Leukemia IND Cleared by FDA for FATE-NK100 with Monoclonal Antibody Therapy in Advanced Solid Tumors Conducted Formal Regulatory Meetings with FDA and MHRA for Engineered Read All »	View HTML Fate Therapeutics Reports First Quarter 2017 Financial Results 34.1 KB
Toggle SummaryMar162017	Fate Therapeutics Reports Fourth Quarter 2016 Financial Results First Subject Treated with ProTmune™ for GvHD Prevention IND Cleared by FDA for FATE-NK100 Natural Killer Cell Product Candidate in AML First-of-Kind Cancer Immunotherapy Derived from Engineered Pluripotent Cell Line to Begin Clinical Translation iPSC-derived NK Cell Research Collaboration Read All »	View HTML Fate Therapeutics Reports Fourth Quarter 2016 Financial Results 38.3 KB

DISCLOSURE NOTICE: The information contained in each press release is as of the date of the respective press release. The Company assumes no obligation to update any information or forward-looking statement contained in any press release as a result of new information or events or developments arising after the date of such press release.